• EI
  • Scopus
  • 食品科学与工程领域高质量科技期刊分级目录第一方阵T1
  • DOAJ
  • EBSCO
  • 北大核心期刊
  • 中国核心学术期刊RCCSE
  • JST China
  • FSTA
  • 中国精品科技期刊
  • 中国农林核心期刊
  • CA
  • WJCI
  • 中国科技核心期刊CSTPCD
  • 中国生物医学SinoMed
中国精品科技期刊2020
杨学芳,董馨忆,普吉霞,等. 辣木叶水提物对大鼠肝纤维化的改善作用及机制[J]. 食品工业科技,2024,45(6):313−320. doi: 10.13386/j.issn1002-0306.2023040136.
引用本文: 杨学芳,董馨忆,普吉霞,等. 辣木叶水提物对大鼠肝纤维化的改善作用及机制[J]. 食品工业科技,2024,45(6):313−320. doi: 10.13386/j.issn1002-0306.2023040136.
YANG Xuefang, DONG Xinyi, PU Jixia, et al. Ameliorative Effects and Mechanism of Aqueous Extract of Moringa oleifera Leaves on Hepatic Fibrosis in Rats[J]. Science and Technology of Food Industry, 2024, 45(6): 313−320. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2023040136.
Citation: YANG Xuefang, DONG Xinyi, PU Jixia, et al. Ameliorative Effects and Mechanism of Aqueous Extract of Moringa oleifera Leaves on Hepatic Fibrosis in Rats[J]. Science and Technology of Food Industry, 2024, 45(6): 313−320. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2023040136.

辣木叶水提物对大鼠肝纤维化的改善作用及机制

Ameliorative Effects and Mechanism of Aqueous Extract of Moringa oleifera Leaves on Hepatic Fibrosis in Rats

  • 摘要: 研究辣木叶(Moringa oleifera Lam,LM)水提物对大鼠肝纤维化(Hepatic Fibrosis,HF)的改善作用和机制。60只雄性SD大鼠随机分为空白组、模型组、秋水仙碱组(100 mg/kg),以及LM高、中、低剂量组(200、100、50 mg/kg),除空白组外,其余组大鼠通过腹腔注射硫代乙酰胺(Thiacetamide,TAA)建立HF模型,自第5周开始灌胃给药。给药结束后检测大鼠体重、肝脏指数、血清丙氨酸氨基转移酶(Alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(Aspartate aminotransferase,AST)、HF指标(血清III型前胶原(procollagen III,PCIII)、IV型胶原(IV collagen IV-C)、层黏蛋白(laminin,LN)、透明质酸(hyaluronidase,HA)、肝脏羟脯胺酸(HYP)、Masson染色观察肝脏纤维组织病变、氧化应激指标(肝脏活性氧(reactive oxygen,ROS)、丙二醛(malondialdehyde,MDA)、超氧化物歧化酶(superoxide dismutase, SOD),实时荧光定量PCR和蛋白质免疫印记检测肝脏转运生长因子β1(transforming growth factor beta1,TGF-β1)/Smads通路基因表达。结果表明,与空白组比较,HF模型组大鼠体重极显著降低(P<0.01),肝脏指数显著增加,血清ALT、AST、PCIII、IV-C、LN、HA和肝脏HYP浓度极显著增加(P<0.01);肝脏组织胶原纤维沉积显著增加,HF病变严重;肝脏ROS和MDA含量极显著增加(P<0.01),SOD活力极显著降低(P<0.01),表明模型组大鼠肝脏处于氧化应激和纤维化病变状态,肝脏功能受损。与模型组比较,LM各剂量组大鼠血清ALT、AST、PCIII、IV-C、LN、HA和肝脏HYP浓度不同程度的降低,肝脏组织胶原纤维沉积显著减少(P<0.05,P<0.01),肝脏ROS和MDA含量显著降低(P<0.05,P<0.01),SOD活力显著升高(P<0.05,P<0.01),表明LM能够降低肝脏氧化应激水平,改善大鼠HF,保护肝脏功能。对TGF-β1/Smads通路基因表达检测发现,模型组TGF-β1、Smad2、Smad3和α-SMA基因mRNA和蛋白表达较空白组显著增加;相较于模型组,LM高、中剂量组大鼠肝脏TGF-β1、Smad2、Smad3和α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)基因表达显著降低(P<0.05,P<0.01),LM低剂量组大鼠肝脏Smad3和α-SMA基因表达显著降低(P<0.05,P<0.01),表明LM可下调HF大鼠肝脏TGF-β1/Smads通路基因表达。LM可能通过下调ROS-TGF-β1/Smads通路,改善TAA诱导的大鼠肝纤维化。

     

    Abstract: To investigate the ameliorative effects and mechanism of Moringa oleifera Lam (LM) leaf aqueous extract on hepatic fibrosis (HF) in rats. 60 male SD rats were randomly divided into normal group, model group, colchicine group (100 mg/kg), and LM high, medium and low dose groups (200, 100 and 50 mg/kg), except for the normal group, rats in the remaining groups were established as HF model by intraperitoneal injection of thioacetamide (TAA) and the corresponding drugs were administered from the 5 th week. At the end of drug administration, rats were examined for body weight, liver index, liver function indexes, including serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). HF indices including serum procollagen type III (PCIII), collagen type IV (IV-C), laminin (LN), hyaluronic acid (HA), liver hydroxyproline acid (HYP). Masson staining was used to observe liver fibrotic tissue lesions. Indicators of Liver oxidative stress, including hepatic reactive oxygen species (ROS), malondialdehyde (MDA), and superoxide dismutase (SOD), were also detected. Real-time quantitative fluorescence PCR and protein immunoblotting were performed to detect hepatic TGF-β1/Smads pathway gene expression. Rats in the HF model group had significantly lower body weight, highly significantly increased liver index, serum ALT, AST, PCIII, IV-C, LN, HA and liver HYP concentrations compared with rats in the normal group (P<0.01). In addition, the liver tissue of rats in the model group showed a significant increase in collagen fibre deposition, severe liver fibrosis, highly significant increase in liver ROS and MDA content, and a highly significant decrease in SOD activity (P<0.01), indicating that the liver of rats in the model group was in a state of oxidative stress and fibrotic lesions, and liver function was impaired. Compared with the model group, serum ALT, AST, PCIII, IV-C, LN, HA and hepatic HYP concentrations were reduced to varying degrees in the LM group rats. In addition, collagen fibre deposition in liver tissue was significantly reduced, liver ROS and MDA content were significantly decreased, and SOD activity was significantly increased in the LM group rats, indicating that LM could reduce the level of liver oxidative stress, ameliorate liver fibrosis and protect liver function in rats (P<0.05, P<0.01). Gene expression detection of the TGF-β1/Smads pathway showed that the mRNA and protein expression of TGF-β1, Smad2, Smad3 and α-SMA genes were significantly increased in the model group compared with the control group. Compared with the model group, the liver TGF-β1, Smad2, Smad3 and α-SMA gene expressions were significantly lower in the LM high and medium dose groups (P<0.05, P<0.01), and the liver Smad3 and α-SMA gene expressions were significantly lower in the LM low dose group (P<0.05, P<0.01), indicating that LM could downregulate liver TGF-β1/Smads pathway gene expression in HF rats. LM would ameliorate TAA-induced liver fibrosis in rats by down-regulating the ROS-TGF-β1/Smads pathway.

     

/

返回文章
返回